

Synthesis of benzo[*c*]chromen-6-ones via novel cyclic aryl–Pd(II)–ester enolate intermediates

Stephen R. Taylor, Alison T. Ung* and Stephen G. Pyne*

Department of Chemistry, University of Wollongong, Wollongong, New South Wales 2522, Australia

Received 24 May 2007; revised 2 August 2007; accepted 23 August 2007

Available online 30 August 2007

Abstract—The examination of the palladium catalysed arylation reactions of mono-iodo derivatives of the phenyl and benzyl esters of benzoic acid, phenylacetic acid and dehydrocinnamic acid has resulted in the formation of benzo[*c*]chromen-6-ones, unexpected cinnamate and succinate products and diphenyl dimers. Many of these products can be rationalised as arising from novel cyclic ArPd(II)–enolate intermediates, formed by intramolecular C–H activation by ArPd(II).

Crown Copyright © 2007 Published by Elsevier Ltd. All rights reserved.


1. Introduction

As a part of a project concerned with the synthesis of lactones of the type **C** we have explored the palladium catalysed arylation reactions of mono-iodo di-aryl esters **A** and **B** as shown in Scheme 1. The formation of benzo[*c*]chromen-6-ones **C** ($m=n=0$) has been readily achieved from palladium catalysed cyclisation of the corresponding mono-iodophenyl benzoate derivative using this strategy.^{1,2} In the successful cases reported, the iodo-substituent is normally attached to the more electron deficient benzoate ring as in the case of **A** ($m=n=0$). The formation of larger lactone rings has not been reported, however, the palladium catalysed arylation reaction has been used to form seven-membered carbocyclic and azepine rings.^{2c,3} We


report here our results from the examination of the palladium catalysed arylation reactions of mono-iodo derivatives of the phenyl and benzyl esters of benzoic acid, phenylacetic acid and dehydrocinnamic acid.

2. Results and discussion

Treatment of the iodo-substituted phenyl benzoate derivatives **1a–c** with 26 mol % $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ in the presence of anhydrous sodium acetate (3 molar equiv) in DMA with heating in a sealed tube at 125 °C for 3 h gave the benzo[*c*]chromen-6-ones **2a–c** in good yields (Scheme 2). In the case of **1c**, a small amount (8%) of the regioisomer **3** was also formed.




Scheme 1.



Scheme 2.


* Corresponding authors. E-mail: spyne@uow.edu.au

When the 2-iodophenyl phenylacetates **4a–c** were treated under identical conditions to **1a–c**, only the products arising from hydrolysis of the ester group of **4a–c** were obtained, even though the NaOAc and DMA had been carefully dried (Scheme 3).




Scheme 3.

Treatment of the phenyl dihydrocinnamate **5** under these conditions resulted in the formation of its cinnamate ester derivative **6** in 59% yield (Scheme 4). A possible mechanism is shown in Scheme 5. This mechanism involves oxidative addition of the aryl iodide to Pd(0) to give the Pd(II)-intermediate **D** from which base (NaOAc)-assisted cyclometallation occurs, via C–H functionalisation, to give the palladacycle **E**. Intermediate **E** can undergo selective protonation to give the Pd(II)-enolate species **F**, which upon β -elimination would give the cinnamate **6** and Pd(II)H. The latter species upon reaction with acetate ion would generate Pd(0) and acetic acid. The functionalisation of sp³C–H and sp²C–H bonds by Pd(II), as in the case of the conversion of intermediate **D** to **E**, has been well documented⁴ and palladium(IV) species have been suggested as intermediates in some of these reactions.^{4b,h,k,o,p} Indeed, oxidative addition of intermediate **D** could provide the palladium(IV) intermediate **G**, which upon reductive elimination would result in intermediate **F** and thus product **6** (Scheme 5).




Scheme 4.

The palladium catalysed reactions of the 2-iodobenzyl 3,4-dimethoxyphenylacetates **7a** and **7b** gave a mixture of two products, which consisted of the benzo[*c*]chromen-6-ones **8a** and **8b**, respectively, and the biphenyls **9a** and **9b**, respectively (Scheme 6). These compounds were readily separated by column chromatography. The 3,4-dimethoxybenzyl 2-iodophenylacetates **10a,b** gave different products. Iodide **10a** gave a separable mixture of the succinate **11** (as a 1.8:1 mixture of diastereomers) and the biphenyl **12**, while **10b** gave the benzo[*c*]chromen-6-one **8b** (Scheme 7). These unexpected products can be rationalised as arising through





Scheme 5. Palladium ligands not shown.


palladium intermediates similar to those suggested in Scheme 5. In Scheme 8, the Pd(II)-palladacycle intermediate **I** is formed from **7a,b** in an analogous fashion to **E** in Scheme 5. Reductive elimination of **I** would provide the



Scheme 6.




Scheme 7.



Scheme 8. Palladium ligands not shown.

benzo[*c*]chromen-6-one **8a** or **8b**. Alternatively, dimerisation of intermediate **H** would give the diphenyl **9a** or **9b**.

In Scheme 9, the ArPd(II) intermediate **J** could undergo deprotonation by NaOAc, perhaps assisted by coordination between the Pd(II) and the ester carbonyl, to give the Pd(II)-palladacycle **K**, which could undergo selective protonation by HOAc to give the *O*-Pd(II)-enolate **L**. The latter would be expected to be in equilibrium with the *C*-Pd(II)-enolate **M**,⁵ which could give rise to the same cyclic Pd(II)-enolate intermediate **I** as suggested in Scheme 8 and then product **8b** via reductive elimination. Alternatively, dimerisation of intermediate **M** could provide the succinate **11**. The proposed Pd(II)-palladacycle **K** is similar to that proposed as an intermediate in the Pd-catalysed intramolecular coupling of *ortho*-bromophenylmethyl ketones to give benzofurans under basic conditions.⁵ However, no benzofuran products could be isolated from our reactions. We assume that because our reactions generate an equivalent of HOAc, from the transformation of intermediate **J** to **K**, protonation of **K** to give **L** is more rapid than benzofuran formation.⁶



Scheme 9. Palladium ligands not shown.

3. Conclusions

In conclusion, the examination of the palladium catalysed arylation reactions of mono-iodo derivatives of the phenyl and benzyl esters of benzoic acid, phenylacetic acid and dehydrocinnamic acid has resulted in the formation of benzo[*c*]chromen-6-ones **2a-c** and **8a,b**, the unexpected cinnamate **6** and the succinate **11** and diphenyl dimers (**9a,b** and **12**). Many of these products can be rationalised as arising from novel cyclic ArPd(II)-enolate intermediates (**E** and **I**). While the formation of ArPd(II)-enolate

intermediates is well documented, these are normally generated from the intermolecular reaction of an in situ generated or preformed enolate anion, using a stronger base than NaOAc as in this study, and a ArPd(II)X species⁷ and not by intramolecular C–H activation by ArPd(II) as we have suggested in this paper.

4. Experimental

4.1. General

All NMR spectra were measured in CDCl₃ solution at 300 MHz (¹H NMR) or 75 MHz (¹³C NMR) unless otherwise indicated. NMR assignments are based on COSY, DEPT and HSQC experiments and sometimes HMBC and NOESY experiments. DCM refers to CH₂Cl₂ and PS refers to petroleum spirit (bp 40–60 °C).

4.2. General methods for ester formation

4.2.1. 3,4-Dimethoxyphenyl 2-iodo-4,5-dimethoxybenzoate 1a. A solution of 2-iodo-4,5-dimethoxybenzoic acid (613 mg, 1.99 mmol), 3,4-dimethoxyphenol (368 mg, 2.39 mmol) and DCC (493 mg, 2.39 mmol), DMAP (73 mg, 0.59 mmol) in DCM (20 mL) was stirred at rt for 18 h under N₂, diluted with DCM (20 mL), filtered and the filtrate washed with water (20 mL) and saturated NaHCO₃ solution (20 mL). The organic phase was dried (MgSO₄), filtered, evaporated and the residue chromatographed, using EtOAc–PS (1:1) as the mobile phase, to yield the title compound as a white solid (671 mg, 76%). Mp 146–148 °C. ¹H NMR: δ 7.64 (s, 1H, Ar-*H*-6), 7.45 (s, 1H, Ar-*H*-3), 6.89 (d, 1H, *J*=8.0 Hz, Ar-*H*-5'), 6.79 (d, 1H, *J*=2.2 Hz, Ar-*H*-2'), 6.78 (dd, 1H, *J*=8.0, 2.2 Hz, Ar-*H*-6'), 3.95 (s, 3H, OCH₃-4), 3.94 (s, 3H, OCH₃-5), 3.89 (s, 3H, OCH₃-4'), 3.88 (s, 3H, OCH₃-3'). ¹³C NMR: δ 164.0 (C=O), 152.2 (Ar-C-OCH₃-4), 149.3 (Ar-C-OCH₃-3'), 148.6 (Ar-C-OCH₃-5), 146.8 (Ar-C-OCH₃-4'), 144.2 (Ar-C-1'), 124.8 (Ar-C-1), 123.9 (Ar-C-H-3), 114.1 (Ar-C-H-6), 112.9 (Ar-C-H-6'), 111.1 (Ar-C-H-5'), 105.8 (Ar-C-H-2'), 85.5 (Ar-C-2), 56.2 (Ar-OCH₃-4), 56.1 (Ar-OCH₃-4'), 56.0 (Ar-OCH₃-5), 55.9 (Ar-OCH₃-3'). MS: *m/z* (EI⁺) 444 (M⁺, 8%), 291 (100%). HRMS (EI⁺): calcd for C₁₇H₁₇IO₆=444.0069 (M⁺), found 444.0053.

4.2.2. 3,4-Dimethoxyphenyl 2-iodo-3,4,5-trimethoxybenzoate 1b. The title compound was prepared in 91% yield (white solid, 483 mg) from 2-iodo-3,4,5-trimethoxybenzoic acid (379 mg, 1.12 mmol) and 3,4-dimethoxyphenol (207 mg, 1.34 mmol) in the presence of DCC (277 mg, 1.34 mmol), DMAP (34 mg, 0.28 mmol) and DCM (10 mL) according to the general esterification method. Mp 98–100 °C. ¹H NMR: δ 7.39 (s, 1H, Ar-*H*-6), 6.90 (dd, 1H, *J*=7.3, 2.4 Hz, Ar-*H*-6'), 6.84 (d, 1H, *J*=2.4 Hz, Ar-*H*-2'), 6.82 (d, 1H, *J*=7.3 Hz, Ar-*H*-5'), 3.95 (s, 3H, OCH₃-5), 3.93 (s, 3H, OCH₃-4), 3.91 (s, 3H, OCH₃-3), 3.90 (s, 3H, OCH₃-3'), 3.89 (s, 3H, OCH₃-4'). ¹³C NMR: δ 165.1 (C=O), 153.9 (Ar-C-OCH₃-3), 153.4 (Ar-C-OCH₃-4), 149.4 (Ar-C-OCH₃-4'), 147.0 (Ar-C-OCH₃-3'), 145.3 (Ar-C-OCH₃-5), 144.2 (Ar-C-1'), 129.9 (Ar-C-1), 112.8 (Ar-C-H-5'), 111.1 (Ar-C-H-6), 110.9 (Ar-C-H-6'), 105.6 (Ar-C-H-2'), 84.5 (Ar-C-2), 61.0 (OCH₃-5), 60.8 (OCH₃-3'), 56.3 (OCH₃-4), 56.1 (OCH₃-3), 55.9 (OCH₃-4'). MS: *m/z* (EI⁺)

474 (M⁺, 6%), 321 (100%). HRMS (EI⁺): calcd for C₁₈H₁₉IO₇=474.0175 (M⁺), found 474.0152.

4.2.3. 3,4-Dimethoxyphenyl 2-iodobenzoate 1c. The title compound was prepared in 93% yield (white solid, 1.15 g) from 2-iodobenzoic acid (800 mg, 3.22 mmol) and 3,4-dimethoxyphenol (547 mg, 3.54 mmol) in the presence of DCC (732 mg, 3.54 mmol), DMAP (130 mg, 1.06 mmol) and DCM (15 mL) according to the general esterification method. Mp 74–76 °C. ¹H NMR: δ 8.06 (d, 1H, J=8.0 Hz, Ar-H-3), 8.02 (dd, 1H, J=8.0, 1.5 Hz, Ar-H-6), 7.47 (t, 1H, J=8.0 Hz, Ar-H-5), 7.21 (dt, 1H, J=8.0, 1.5 Hz, Ar-H-4), 6.99 (d, 1H, J=8.0 Hz, Ar-H-5'), 6.81 (dd, 1H, J=8.0, 2.5 Hz, Ar-H-6'), 6.80 (d, 1H, J=2.5 Hz, Ar-H-2'), 3.89 (s, 3H, OCH₃-3'), 3.88 (s, 3H, OCH₃-4'). ¹³C NMR: δ 165.0 (C=O), 149.3 (Ar-C-OCH₃-4), 147.0 (Ar-C-OCH₃-3), 144.2 (Ar-C-1'), 141.5 (Ar-C-H-3), 134.1 (Ar-C-1), 133.1 (Ar-C-H-4), 131.4 (Ar-C-H-6), 127.9 (Ar-C-H-5), 112.8 (Ar-C-H-6'), 111.1 (Ar-C-H-5'), 105.6 (Ar-C-H-2'), 94.5 (Ar-C-2), 56.1 (Ar-OCH₃-4'), 55.9 (Ar-OCH₃-3'). MS: *m/z* (EI⁺) 384 (M⁺, 6%), 125 (100%). HRMS (EI⁺): calcd for C₁₅H₁₃IO₄=383.9858 (M⁺), found 383.9862.

4.2.4. 3,4-Dimethoxyphenyl 2-iodo-4,5-dimethoxyphenylacetate 4a. The title compound was prepared in 76% yield (sticky white solid, 740 mg) from 2-iodo-4,5-dimethoxyphenylacetic acid (686 mg, 2.12 mmol) and 3,4-dimethoxyphenol (361 mg, 2.34 mmol) in the presence of DCC (483 mg, 2.34 mmol), DMAP (73 mg, 0.59 mmol) and DCM (10 mL) according to esterification method. Mp 76–78 °C. ¹H NMR: δ 7.27 (s, 1H, Ar-H-3), 6.90 (s, 1H, Ar-H-6), 6.82 (s, 1H, Ar-H-5'), 6.69 (s, 1H, Ar-H-2'), 6.68 (s, 1H, Ar-H-6'), 3.95 (s, 2H, Ar-CH₂), 3.876 (s, 3H, OCH₃-3), 3.870 (s, 3H, OCH₃-5), 3.86 (s, 3H, OCH₃-4'), 3.85 (s, 3H, OCH₃-4). ¹³C NMR: δ 169.5 (C=O), 149.4 (Ar-C-OCH₃-4), 149.3 (Ar-C-OCH₃-3'), 148.8 (Ar-C-OCH₃-3), 146.9 (Ar-C-OCH₃-4'), 144.3 (Ar-C-1'), 129.5 (Ar-C-1), 121.6 (Ar-C-H-3), 113.4 (Ar-C-H-6), 112.7 (Ar-C-H-6'), 111.1 (Ar-C-H-5'), 105.6 (Ar-C-H-2'), 88.9 (Ar-C-2), 56.1 (2×OCH₃-3,5), 55.9 (2×OCH₃-4,4'), 45.7 (Ar-CH₂). MS: *m/z* (EI⁺) 458 (M⁺, 3%), 149 (100%). HRMS (EI⁺): calcd for C₁₈H₁₉IO₆=458.0226 (M⁺), found 458.0233.

4.2.5. 2-Iodophenyl 3,4-dimethoxyphenylacetate 4b. The title compound was prepared in 91% yield (clear oil, 1.65 g) from 3,4-dimethoxyphenylacetic acid (980 mg, 4.99 mmol) and 2-iodophenol (1.0 g, 4.54 mmol) in the presence of DCC (1.03 mg, 4.99 mmol), DMAP (166 mg, 1.36 mmol) and DCM (20 mL) according to esterification method. Mp 52–54 °C. ¹H NMR: δ 7.79 (d, 1H, J=8.0 Hz, Ar-H-3'), 7.32 (t, 1H, J=7.5 Hz, Ar-H-5'), 7.05 (d, 1H, J=7.5 Hz, Ar-H-6'), 6.96 (br s, 1H, Ar-H-2), 6.96–6.93 (m, 1H, Ar-H-6), 6.94 (t, 1H, J=8.0 Hz, Ar-H-4'), 6.85 (d, 1H, J=8.0 Hz, Ar-H-5), 3.89 (s, 3H, OCH₃-3), 3.869 (s, 3H, OCH₃-4), 3.864 (s, 2H, Ar-CH₂). ¹³C NMR: δ 169.2 (C=O), 151.0 (Ar-C-1'), 148.8 (Ar-C-OCH₃-4), 148.3 (Ar-C-OCH₃-3), 139.3 (Ar-C-H-3'), 129.2 (Ar-C-H-5'), 127.5 (Ar-C-H-4'), 125.3 (Ar-C-1), 122.8 (Ar-C-H-6'), 121.7 (Ar-C-H-6), 112.7 (Ar-C-H-2), 111.1 (Ar-C-H-5), 90.1 (Ar-C-H-2'), 55.8 (Ar-OCH₃-4), 55.7 (Ar-OCH₃-3), 40.8 (Ar-CH₂). MS: *m/z* (EI⁺) 398 (M⁺, 46%), 151

(100%). HRMS (EI⁺): calcd for C₁₆H₁₅IO₄=398.0015 (M⁺), found 398.0012.

4.2.6. 3,4-Dimethoxyphenyl 2-iodophenylacetate 4c. The title compound was prepared in 92% yield (clear oil, 1.41 g) from 2-iodophenylacetic acid (1.00 g, 3.81 mmol) and 3,4-dimethoxyphenol (647 mg, 4.19 mmol) in the presence of DCC (866 mg, 4.19 mmol), DMAP (140 mg, 1.14 mmol) and DCM (20 mL) according to esterification method. Mp 90–92 °C. ¹H NMR: δ 7.87 (d, 1H, J=7.5 Hz, Ar-H-3), 7.37 (d, 1H, J=7.5 Hz, Ar-H-6), 7.33 (t, 1H, J=7.5 Hz, Ar-H-5), 6.98 (t, 1H, J=7.5 Hz, Ar-H-4), 6.81 (d, 1H, J=8.0 Hz, Ar-H-5'), 6.69 (d, 1H, J=1.5 Hz, Ar-H-2'), 6.68 (dd, 1H, J=8.0, 1.5 Hz, Ar-H-6'), 4.01 (s, 2H, Ar-CH₂), 3.84 (s, 3H, OCH₃-3'), 3.83 (s, 3H, OCH₃-4'). ¹³C NMR: δ 169.1 (C=O), 149.1 (Ar-C-OCH₃-3'), 146.7 (Ar-C-OCH₃-4'), 144.2 (Ar-C-1'), 139.4 (Ar-C-H-3), 137.2 (Ar-C-1), 130.7 (Ar-C-H-6), 129.0 (Ar-C-H-4), 128.4 (Ar-C-H-5), 112.6 (Ar-C-H-6'), 111.0 (Ar-C-H-5'), 105.5 (Ar-C-H-2'), 100.8 (Ar-C-2), 56.0 (Ar-OCH₃-3'), 55.8 (Ar-OCH₃-4'), 46.1 (Ar-CH₂). MS: *m/z* (EI⁺) 398 (M⁺, 5%), 154 (100%). HRMS (EI⁺): calcd for C₁₆H₁₅IO₄=398.0015 (M⁺), found 398.0002.

4.2.7. 3,4-Dimethoxyphenyl 3-(2-iodo-4,5-dimethoxyphenyl)propionate 5. The title compound was prepared in 81% yield (cream solid, 669 mg) from 3-(2-iodo-4,5-dimethoxyphenyl)propanoic acid (566 mg, 1.68 mmol) and 3,4-dimethoxyphenol (286 mg, 1.85 mmol) in the presence of DCC (382 mg, 1.85 mmol), DMAP (51 mg, 0.42 mmol) and DCM (13 mL) according to the general esterification method. Mp 100–102 °C. ¹H NMR: δ 7.22 (s, 1H, Ar-H-3), 6.83 (s, 1H, Ar-H-6), 6.81 (d, 1H, J=8.7 Hz, Ar-H-5'), 6.58 (dd, 1H, J=8.7, 2.5 Hz, Ar-H-6'), 6.55 (d, 1H, J=2.5 Hz, Ar-H-2'), 3.83 (s, 3H, OCH₃), 3.84 (s, 3H, OCH₃), 3.83 (s, 3H, OCH₃), 3.82 (s, 3H, OCH₃), 3.09 (t, 2H, J=7.3, Ar-CH₂), 2.83 (t, 2H, J=7.3, Ar-CH₂-CH₂). ¹³C NMR: δ 171.3 (C=O), 149.3 (2×Ar-C-OCH₃-4,4'), 148.1 (Ar-C-OCH₃-5), 146.7 (Ar-C-OCH₃-3'), 144.1 (Ar-C-1'), 135.0 (Ar-C-1), 121.7 (Ar-C-H-3), 112.7 (Ar-C-H-6), 112.6 (Ar-C-H-6'), 111.0 (Ar-C-H-5'), 105.5 (Ar-C-H-2'), 87.7 (Ar-C-2), 56.1 (2×Ar-OCH₃-3',5), 55.8 (2×Ar-OCH₃-4,4'), 35.4 (Ar-CH₂), 34.6 (Ar-CH₂-CH₂). MS: *m/z* (EI⁺) 472 (M⁺, 19%), 154 (100%). HRMS (EI⁺): calcd for C₁₉H₂₁IO₆=472.0383 (M⁺), found 472.0373.

4.2.8. 2-Iodobenzyl (3,4-dimethoxyphenyl)acetate 7a. The title compound was prepared in 81% yield (clear oil, 1.42 g) from 3,4-dimethoxyphenylacetic acid (922 mg, 4.70 mmol) and 2-iodobenzyl alcohol (1.00 g, 4.27 mmol) in the presence of DCC (969 mg, 4.70 mmol), DMAP (156 mg, 1.28 mmol) and DCM (20 mL) according to the general esterification method. Mp 52–54 °C. ¹H NMR: δ 7.82 (d, 1H, J=7.5 Hz, Ar-H-3'), 7.30 (t, 1H, J=7.5 Hz, Ar-H-5'), 7.28 (d, 1H, J=7.5 Hz, Ar-H-6'), 6.99 (dt, 1H, J=7.5, 2.0 Hz, Ar-H-4'), 6.84 (d, 1H, J=8.5 Hz, Ar-H-6), 6.83 (br s, 1H, Ar-H-2), 6.80 (d, 1H, J=8.5 Hz, Ar-H-5), 5.13 (s, 2H, Ar-CH₂-O), 3.85 (s, 3H, OCH₃-4), 3.84 (s, 3H, OCH₃-3), 3.63 (s, 2H, Ar-CH₂-CO). ¹³C NMR: δ 171.1 (C=O), 148.8 (Ar-C-OCH₃-3), 148.0 (Ar-C-OCH₃-4), 139.3 (Ar-C-H-3'), 138.1 (Ar-C-1'), 129.7 (Ar-C-H-4'), 129.3 (Ar-C-H-6'), 128.1 (Ar-C-H-5'),

126.0 (Ar-C-1), 121.4 (Ar-C-H-6), 112.3 (Ar-C-H-2), 111.1 (Ar-C-H-5), 98.1 (Ar-C-2'), 70.1 (Ar-CH₂-O), 55.78 (Ar-OCH₃-4), 55.73 (Ar-OCH₃-3), 40.4 (Ar-CH₂-CO). MS: *m/z* (EI⁺) 412 (M⁺, 62%), 151 (100%). HRMS (EI⁺): calcd for C₁₇H₁₇IO₄=412.0171 (M⁺), found 412.0151.

4.2.9. 2-Iodo-4,5-dimethoxybenzyl 3,4-dimethoxyphenylacetate 7b. The title compound was prepared in 70% yield (92% based on recovered starting material orange solid, 720 mg) from 3,4-dimethoxyphenylacetic acid (474 mg, 2.41 mmol) and 2-iodo-4,5-dimethoxybenzyl alcohol (645 mg, 2.19 mmol) in the presence of DCC (498 mg, 2.41 mmol), DMAP (80 mg, 0.69 mmol) and DCM (10 mL) according to the general esterification method. (2-Iodo-4,5-dimethoxybenzyl alcohol (159 mg) was recovered from the reaction.) Mp 88–90 °C. ¹H NMR: δ 7.23 (s, 1H, Ar-H-3'), 6.84 (d, 1H, *J*=7.0 Hz, Ar-H-5), 6.83–6.81 (m, 1H, Ar-H-6), 6.81 (d, 1H, *J*=2.4 Hz, Ar-H-2), 6.79 (s, 1H, Ar-H-6'), 5.09 (s, 2H, Ar-CH₂-O), 3.86 (s, 6H, OCH₃-4',5'), 3.85 (s, 3H, OCH₃-3), 3.76 (s, 3H, OCH₃-4), 3.62 (s, 1H, Ar-CH₂-CO). ¹³C NMR: δ 171.3 (C=O), 149.3 (Ar-C-OCH₃-4), 149.2 (Ar-C-OCH₃-4'), 148.8 (Ar-C-OCH₃-5'), 148.1 (Ar-C-OCH₃-3), 130.6 (Ar-C-1'), 126.2 (Ar-C-1), 121.6 (Ar-C-H-3'), 121.4 (Ar-C-H-5), 112.6 (Ar-C-H-6'), 112.4 (Ar-C-H-6), 111.1 (Ar-C-H-2), 86.9 (Ar-C-2'), 70.2 (Ar-CH₂-O), 56.1 (Ar-OCH₃-3), 55.85 (2×Ar-OCH₃-4,4'), 55.83 (Ar-OCH₃-5'), 40.8 (Ar-CH₂-CO). MS: *m/z* (EI⁺) 472 (M⁺, 13%), 151 (100%). HRMS (EI⁺): calcd for C₁₉H₂₁IO₆=472.0383 (M⁺), found 472.0388.

4.2.10. 3,4-Dimethoxybenzyl (2-iodophenyl)acetate 10a. The title compound was prepared in 91% yield (clear oil, 1.42 g) from 2-iodophenylacetic acid (1.0 g, 3.82 mmol) and 3,4-dimethoxybenzyl alcohol (706 mg, 4.19 mmol) in the presence of DCC (866 mg, 4.19 mmol), DMAP (140 mg, 1.14 mmol) and DCM (20 mL) according to esterification method. ¹H NMR: δ 7.83 (d, 1H, *J*=8.0 Hz, Ar-H-3), 7.29 (d, 1H, *J*=8.0 Hz, Ar-H-6), 7.28 (t, 1H, *J*=8.0 Hz, Ar-H-5), 6.94 (t, 1H, *J*=8.0 Hz, Ar-H-4), 6.90 (d, 1H, *J*=8.0 Hz, Ar-H-6'), 6.85 (br s, 1H, Ar-H-2'), 6.81 (d, 1H, *J*=8.0 Hz, Ar-H-5'), 5.10 (s, 2H, Ar-CH₂-O), 3.86 (s, 3H, OCH₃-3'), 3.84 (s, 3H, OCH₃-4'), 3.82 (s, 2H, Ar-CH₂-CO). ¹³C NMR: δ 170.2 (C=O), 148.9 (Ar-C-OCH₃-4'), 148.8 (Ar-C-OCH₃-3'), 139.3 (Ar-C-H-3), 137.6 (Ar-C-1), 130.5 (Ar-C-H-5), 128.7 (Ar-C-H-4), 128.3 (Ar-C-H-6), 128.1 (Ar-C-1'), 121.0 (Ar-C-H-6'), 111.5 (Ar-C-H-2'), 110.8 (Ar-C-H-5'), 100.9 (Ar-C-2), 66.7 (Ar-CH₂-O), 55.79 (Ar-OCH₃-4'), 55.78 (Ar-OCH₃-3'), 46.2 (Ar-CH₂-CO). MS: *m/z* (EI⁺) 412 (M⁺, 48%), 151 (100%). HRMS (EI⁺): calcd for C₁₇H₁₇IO₄=412.0171, found 412.0158.

4.2.11. 3,4-Dimethoxybenzyl 2-iodo-4,5-dimethoxyphenylacetate 10b. The title compound was prepared in 77% yield (white solid, 452 mg) from 2-iodo-3,4-dimethoxyphenylacetic acid (400 mg, 1.24 mmol) and 3,4-dimethoxybenzyl alcohol (229 mg, 1.36 mmol) in the presence of DCC (282 mg, 1.36 mmol), DMAP (45 mg, 0.37 mmol) and DCM (10 mL) according to esterification method. Mp 96–98 °C. ¹H NMR: δ 7.23 (s, 1H, Ar-H-3), 6.91 (dd, 1H, *J*=8.0, 2.0 Hz, Ar-H-6'), 6.88 (d, 1H, *J*=2.0 Hz, Ar-H-2'), 6.83 (d, 1H, *J*=8.0 Hz, Ar-H-5'), 6.78 (s, 1H, Ar-H-6),

5.11 (s, 2H, Ar-CH₂-O), 3.87 (s, 3H, OCH₃-3'), 3.86 (s, 3H, OCH₃-4'), 3.84 (s, 3H, OCH₃-5), 3.81 (s, 3H, OCH₃-4), 3.76 (s, 2H, Ar-CH₂-CO). ¹³C NMR: δ 170.6 (C=O), 149.0 (Ar-C-OCH₃-4), 148.9 (2×Ar-C-OCH₃-4',5'), 148.6 (Ar-C-OCH₃-5), 129.9 (Ar-C-1), 128.2 (Ar-C-1'), 121.5 (Ar-C-H-3), 121.1 (Ar-C-H-6'), 113.2 (Ar-C-H-6), 111.6 (Ar-C-H-5'), 110.8 (Ar-C-H-2'), 88.8 (Ar-C-2), 66.7 (Ar-CH₂-O), 56.1 (Ar-OCH₃-5'), 55.87 (2×Ar-OCH₃-4,4'), 55.86 (Ar-OCH₃-3'), 45.7 (Ar-CH₂-CO). MS: *m/z* (EI⁺) 472 (M⁺, 9%), 151 (100%). HRMS (ES⁺): calcd for C₁₉H₂₂IO₆=473.0461 (M+H⁺), found 473.0443.

4.3. General method for palladium-mediated arylation

4.3.1. 2,3,8,9-Tetramethoxy-6H-benzo[*c*]chromen-6-one 2a. Compound **1a** (100 mg, 0.22 mmol), (Ph₃P)₂PdCl₂ (41 mg, 0.058 mmol), anhydrous NaOAc (55 mg, 0.67 mmol) and DMA (25 mL) were combined in an ACE[®] pressure tube. The solution was degassed for 20 min with Ar, the vessel sealed and heated at 120 °C for 3 h. The tube was cooled to rt and the solid residue removed by filtration. The filtrate was diluted with 20 mL of 10% HCl solution and extracted with EtOAc (2×20 mL). The combined extracts were washed with H₂O (4×20 mL), dried (MgSO₄), filtered, evaporated and the title compound was isolated as a white film (57.2 mg, 80%) by flash silica gel chromatography using DCM-PS-EtOAc (2:2:1) as the eluent. Mp 217–219 °C. ¹H NMR: δ 7.69 (s, 1H, Ar-H-7), 7.24 (s, 1H, Ar-H-10), 7.22 (s, 1H, Ar-H-1), 6.83 (s, 1H, Ar-H-4), 4.11 (s, 3H, OCH₃-8), 4.02 (s, 3H, OCH₃-2), 3.99 (s, 3H, OCH₃-9), 3.94 (s, 3H, OCH₃-3). ¹³C NMR: δ 161.4 (C=O), 155.1 (Ar-C-OCH₃-8), 150.9 (Ar-C-OCH₃-3), 149.3 (Ar-C-OCH₃-9), 146.3 (Ar-C-4a), 146.0 (Ar-C-OCH₃-2), 130.3 (Ar-C-7a), 113.3 (Ar-C-10a), 110.5 (Ar-C-H-7), 110.0 (Ar-C-1a), 103.8 (Ar-C-H-10), 102.0 (Ar-C-H-1), 100.8 (Ar-C-H-4), 56.6 (Ar-OCH₃-2), 56.3 (Ar-OCH₃-8), 56.2 (Ar-OCH₃-9), 56.1 (Ar-OCH₃-3). MS: *m/z* (EI⁺) 316 (M⁺, 100%). HRMS (CI⁺): calcd for C₁₇H₁₇O₆=317.1025 (M+H⁺), found 317.1026 (M⁺).

4.3.2. 2,3,8,9,10-Pentamethoxy-6H-benzo[*c*]chromen-6-one 2b. The title compound was prepared in 85% yield (white solid, 63 mg) from **1b** (100 mg, 0.21 mmol), in the presence of (Ph₃P)₂PdCl₂ (39 mg, 0.055 mmol), NaOAc (52 mg, 0.63 mmol) and DMA (25 mL) according to the general arylation method described above. Mp 148–150 °C. ¹H NMR: δ 8.39 (s, 1H, Ar-H-7), 7.72 (s, 1H, Ar-H-1), 6.86 (s, 1H, Ar-H-4), 4.05 (s, 3H, OCH₃-8), 4.00 (s, 3H, OCH₃-9), 3.99 (s, 3H, OCH₃-10), 3.98 (s, 3H, OCH₃-3), 3.94 (s, 3H, OCH₃-2). ¹³C NMR: δ 161.3 (C=O), 152.8 (Ar-C-OCH₃-10), 150.1 (Ar-C-OCH₃-9), 149.9 (Ar-C-OCH₃-2), 148.9 (Ar-C-OCH₃-3), 145.7 (Ar-C-OCH₃-8), 145.4 (Ar-C-4a), 123.1 (Ar-C-7a), 116.2 (Ar-C-10a), 109.4 (Ar-C-1a), 108.1 (Ar-C-H-7), 107.9 (Ar-C-H-1), 100.3 (Ar-C-H-4), 61.1 (Ar-OCH₃-8), 60.6 (Ar-OCH₃-3), 56.2 (Ar-OCH₃-9), 56.1 (Ar-OCH₃-10), 56.0 (Ar-OCH₃-2). MS: *m/z* (CI⁺) 347 (M+H⁺, 100%). HRMS (CI⁺): calcd for C₁₈H₁₉O₇=347.1131 (M+H⁺), found 347.1132.

4.3.3. 2,3-Dimethoxy-6H-benzo[*c*]chromen-6-one 2c and 1,2-dimethoxy-6H-benzo[*c*]chromen-6-one 3. Compound **2c** was prepared in 71% yield (white solid, 47.3 mg) from

1c (100 mg, 0.26 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (39 mg, 0.067 mmol), NaOAc (64 mg, 0.78 mmol) and DMA (25 mL) according to the general arylation method described above. Regioisomer **3** was also isolated from the reaction as a white solid (9.2 mg, 8%). NMR data were consistent with the literature for **2c** and **3**.⁸

4.3.4. 3,4-Dimethoxyphenyl (2E)-3-(3,4-dimethoxyphenyl)acrylate **6**.

The title compound was prepared in 59% yield (yellow film, 43 mg) from **5** (100 mg, 0.20 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (37 mg, 0.053 mmol), NaOAc (51 mg, 0.61 mmol) and DMA (25 mL) according to the general arylation method described above. While this is a known compound NMR data were not reported.⁹ ¹H NMR: δ 7.80 (d, 1H, $J=15.9$ Hz, Ar-CH=CH), 7.16 (dd, 1H, $J=8.1$, 1.5 Hz, Ar-H-6), 7.10 (d, 1H, $J=1.5$ Hz, Ar-H-2), 6.89 (d, 1H, $J=8.1$ Hz, Ar-H-5), 6.86 (d, 1H, $J=9.3$ Hz, Ar-H-5'), 6.72 (d, 1H, $J=2.7$ Hz, Ar-H-2'), 6.71 (dd, 1H, $J=9.3$, 2.7 Hz, Ar-H-6'), 6.48 (d, 1H, $J=15.9$ Hz, Ar-CH=CH), 3.92 (s, 6H, $2\times\text{OCH}_3$ -3,4), 3.88 (s, 3H, OCH_3 -3'), 3.86 (s, 3H, OCH_3 -4'). ¹³C NMR: δ 166.0 (C=O), 151.4 (Ar-C-OCH₃-3), 149.3 (Ar-C-OCH₃-4), 149.2 (Ar-C-OCH₃-4'), 146.7 (Ar-C-OCH₃-3'), 146.4 (Ar-CH=CH), 144.4 (Ar-C-1'), 127.1 (Ar-CH=CH), 122.9 (Ar-C-H-6), 114.7 (Ar-CH=CH), 112.9 (Ar-C-H-6'), 111.1 (Ar-C-H-5), 111.0 (Ar-C-H-5'), 109.7 (Ar-C-H-2), 105.8 (Ar-C-H-2'), 56.1 (Ar-OCH₃), 55.96 (Ar-OCH₃), 55.94 (Ar-OCH₃), 55.8 (Ar-OCH₃). MS: m/z (EI⁺) 344 (M⁺, 13%), 191 (100%). HRMS (EI⁺): calcd for C₁₉H₂₀O₆=344.1260 (M⁺), found 344.1256.

4.3.5. 4-(3,4-Dimethoxyphenyl)-1,4-dihydro-3H-isochromen-3-one **8a and 2,2'-(dimethylenebiphenyl-2,2'-diyl)[di(3,4-dimethoxyphenyl)]diacetate **9a**.** Compounds **8a** (white film, 20 mg, 29%) and **9a** (white film, 31 mg, 30%) were prepared from **7a** (100 mg, 0.24 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (44 mg, 0.063 mmol), NaOAc (60 mg, 0.73 mmol) and DMA (25 mL) according to the general arylation method described above.

Compound 8a: ¹H NMR: δ 7.38 (d, 1H, $J=8.4$ Hz, Ar-H-5), 7.37 (t, 1H, $J=8.4$ Hz, Ar-H-7), 7.29 (d, 1H, $J=8.4$ Hz, Ar-H-8), 7.15 (t, 1H, $J=8.4$ Hz, Ar-H-6), 6.81 (d, 1H, $J=2.1$ Hz, Ar-H-2'), 6.78 (d, 1H, $J=8.2$ Hz, Ar-H-5'), 6.53 (dd, 1H, $J=8.2$, 2.1 Hz, Ar-H-6'), 5.23 (ABq, 2H, $J=16.5$ Hz, Ar-CH₂-O), 4.95 (Ar-CH-CO), 3.85 (s, 3H, OCH_3 -4'), 3.82 (s, 3H, OCH_3 -3'). ¹³C NMR: δ 171.6 (C=O), 149.6 (Ar-C-OCH₃-3'), 149.0 (Ar-C-OCH₃-4'), 134.4 (Ar-C-5a), 132.2 (Ar-C-8a), 129.2 (Ar-C-H-5), 128.2 (Ar-C-H-6), 128.0 (Ar-C-H-7), 126.7 (Ar-C-1'), 125.0 (Ar-C-H-8), 120.5 (Ar-C-H-6'), 111.7 (Ar-C-H-2'), 111.3 (Ar-C-H-5'), 69.7 (Ar-CH₂-O), 56.1 ($2\times\text{Ar-OCH}_3$ -3,4), 51.5 (Ar-CH-CO). MS: m/z (EI⁺) 284 (M⁺, 73%), 209 (100%). HRMS (EI⁺): calcd for C₁₇H₁₆O₄=284.1048 (M⁺), found 284.1057.

Compound 9a: ¹H NMR: δ 7.37 (dd, 2H, $J=7.5$, 1.5 Hz, Ar-H-3'), 7.33 (dt, 2H, $J=7.5$, 1.5 Hz, Ar-H-5'), 7.28 (dt, 2H, $J=7.5$, 1.5 Hz, Ar-H-4'), 7.11 (dd, 2H, $J=7.5$, 1.0 Hz, Ar-H-6'), 6.78 (d, 2H, $J=9.0$ Hz, Ar-H-5), 6.74 (dd, 2H, $J=9.0$, 1.5 Hz, Ar-H-6), 6.73 (br s, 2H, Ar-H-2), 4.83 (ABq, 4H, $J=12.5$ Hz, Ar-CH₂-O), 3.85 (s, 6H, OCH_3 -4), 3.81 (s, 6H, OCH_3 -3), 3.48 (s, 4H, Ar-CH₂-CO).

¹³C NMR: δ 171.2 (C=O), 148.8 (Ar-C-OCH₃-3), 148.1 (Ar-C-OCH₃-4), 139.6 (Ar-C-H-3'), 133.7 (Ar-C-1'), 129.9 (Ar-C-2'), 128.9 (Ar-C-H-3'), 127.9 ($2\times\text{Ar-C-H-4',5'}$), 126.2 (Ar-C-1), 121.4 (Ar-C-H-6), 112.3 (Ar-C-H-2), 111.1 (Ar-C-H-5), 64.5 (Ar-CH₂-O), 55.8 (Ar-OCH₃-4), 55.7 (Ar-OCH₃-3), 40.7 (Ar-CH₂-CO). MS: m/z (EI⁺) 570 (M⁺, 47%), 151 (100%). HRMS (EI⁺): calcd for C₃₄H₃₄O₈=570.2254 (M⁺), found 570.2271.

4.3.6. 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-1,4-dihydro-3H-isochromen-3-one **8b and 2,2'-[dimethylene(4,4',5,5'-tetramethoxy)biphenyl-2,2'-diyl](di(3,4-dimethoxyphenyl))diacetate **9b**.** Compounds **8b** (yellow film, 21 mg, 29%) and **9b** (orange film, 39 mg, 46%) were prepared from **7b** (115 mg, 0.24 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (44 mg, 0.063 mmol), NaOAc (60 mg, 0.73 mmol) and DMA (25 mL) according to the general arylation method described above.

Compound 8b: the spectral data for this compound is given below in Section 4.3.7.

Compound 9b: ¹H NMR: δ 6.84 (s, 2H, Ar-H-6'), 6.78 (d, 2H, $J=9.0$ Hz, Ar-H-5), 6.76 (d, 2H, $J=9.0$ Hz, Ar-H-6), 6.75 (br s, 2H, Ar-H-2), 6.69 (s, 2H, Ar-H-3'), 4.81 (ABq, 4H, $J=12.0$ Hz, Ar-CH₂-O), 3.85 (s, 6H, OCH_3 -5'), 3.84 (s, 6H, OCH_3 -4'), 3.81 (s, 6H, OCH_3 -3), 3.80 (s, 6H, OCH_3 -4), 3.51 (s, 4H, Ar-CH₂-CO). ¹³C NMR: δ 171.3 (C=O), 148.9 (Ar-C-OCH₃-4'), 148.4 ($2\times\text{Ar-C-OCH}_3$ -3,4), 148.3 (Ar-C-OCH₃-3'), 132.3 (Ar-C-1'), 126.3 (Ar-C-2'), 126.2 (Ar-C-1), 121.3 (Ar-C-H-6), 113.1 (Ar-C-H-3), 112.3 (Ar-C-H-2), 111.9 (Ar-C-H-6), 111.1 (Ar-C-H-5), 64.4 (Ar-CH₂-O), 56.0 (Ar-OCH₃-3), 55.9 (Ar-OCH₃-4), 55.8 (Ar-OCH₃-4'), 55.7 (Ar-OCH₃-3'), 40.8 (Ar-CH₂-CO). MS: m/z (EI⁺) 690 (M⁺, 11%), 368 (100%). HRMS (EI⁺): calcd for C₃₈H₄₂O₁₂=690.2676 (M⁺), found 690.2679.

4.3.7. 4-(3,4-Dimethoxyphenyl)-6,7-dimethoxy-1,4-dihydro-3H-isochromen-3-one **8b.** The title compound was also prepared in 21% yield (yellow film, 15 mg) from 3,4-dimethoxybenzyl (2-iodo-4,5-dimethoxyphenyl)acetate (115 mg, 0.24 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (44 mg, 0.063 mmol), NaOAc (60 mg, 0.73 mmol) and DMA (25 mL) according to the general arylation method described above. ¹H NMR: δ 6.84 (d, 1H, $J=2.0$ Hz, Ar-H-2'), 6.77 (s, 1H, Ar-H-5), 6.78 (d, 1H, $J=8.7$ Hz, Ar-H-5'), 6.65 (s, 1H, Ar-H-8), 6.51 (dd, 1H, $J=8.7$, 2.0 Hz, Ar-H-6'), 5.17 (ABq, 2H, $J=13.5$ Hz, Ar-CH₂-O), 4.89 (Ar-CH-CO), 3.92 (s, 3H, OCH_3 -6), 3.85 (s, 3H, OCH_3 -7), 3.84 (s, 3H, OCH_3 -3'), 3.83 (s, 3H, OCH_3 -4'). ¹³C NMR: δ 171.5 (C=O), 149.8 (Ar-C-OCH₃-3), 149.6 (Ar-C-OCH₃-4'), 149.0 (Ar-C-OCH₃-4), 148.8 (Ar-C-OCH₃-5'), 127.0 (Ar-C-5a), 126.2 (Ar-C-1'), 124.3 (Ar-C-8a), 120.2 (Ar-C-H-6'), 111.5 (Ar-C-H-2'), 111.3 (Ar-C-H-5'), 111.2 (Ar-C-H-8), 108.1 (Ar-C-H-5), 69.6 (Ar-CH₂-O), 56.4 (Ar-OCH₃), 56.3 (Ar-OCH₃), 56.2 (Ar-OCH₃), 56.1 (Ar-OCH₃), 50.9 (Ar-CH-CO). MS: m/z (EI⁺) 344 (M⁺, 46%), 269 (100%). HRMS (CI⁺): calcd for C₁₉H₂₁O₆=345.1338 (M+H⁺), found 345.1327.

4.3.8. Di(3,4-dimethoxybenzyl) 2,3-diphenylsuccinate **11 and di(3,4-dimethoxybenzyl) 2,2'-biphenyl-2,2'-**

diylacetate 12. Compound **11** was prepared in 27% yield (clear film, 19 mg) from **10a** (100 mg, 0.24 mmol) in the presence of $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ (65 mg, 0.093 mmol), NaOAc (60 mg, 0.73 mmol) and DMA (25 mL) according to the general arylation method described above, and with HPLC separation of **12** (clear film, 4 mg, 7%) from the reaction mixture. The major and minor diastereomers could not be separated by HPLC and are reported together. The diastereomeric ratio was major–minor=1.8:1. NMR signals for the minor diastereomer are shown in brackets.

Compound 11: ^1H NMR: δ 7.47 (dd, 2H, $J=7.5, 2.1$ Hz, Ar–H-4), 7.13 (t, 4H, $J=7.5$ Hz, Ar–H-3,5), 7.03 (dd, 4H, Ar–H-2,6), 6.73 (d, 2H, $J=7.8$ Hz, Ar–H-5'), 6.59 (dd, 2H, $J=7.8, 2.1$ Hz, Ar–H-6'), 6.48 (d, 2H, $J=2.1$ Hz, Ar–H-2'), 5.04 (4.76) (ABq, 4H, $J=12.3$ Hz, (ABq, 4H, $J=12.0$ Hz), Ar–CH₂–O), 4.30 (4.43) (s, 2H, Ar–CH–CO), 3.85 (3.85) (s, 3H, OCH₃-3'), 3.74 (3.69) (s, 3H, OCH₃-4'). ^{13}C NMR: δ 172.8 (171.4) (C=O), 148.9 (Ar–C–OCH₃-3'), 148.8 (Ar–C–OCH₃-4'), 135.5 (136.1) (Ar–C–H-2'), 128.5 (128.6) (Ar–C–H-4), 128.3 (128.2) (Ar–C–H-3,5), 128.4 (Ar–C-1), 128.0 (127.9) (Ar–C-1'), 127.4 (127.8) (Ar–C–H-2,6), 120.8 (120.5) (Ar–C–H-6'), 110.9 (111.2) (Ar–C–H-2'), 110.7 (110.9) (Ar–C–H-5'), 66.6 (Ar–CH₂–O), 55.8 (Ar–OCH₃), 55.7 (55.6) (Ar–OCH₃), 54.8 (54.9) (Ar–CH–CO). MS: m/z (EI⁺) 570 (M⁺, 10%), 151 (100%). HRMS (EI⁺): calcd for C₃₄H₃₄O₈=570.2253 (M⁺), found 570.2231.

Compound 12: ^1H NMR: δ 7.30–7.26 (m, 4H, Ar–H-5,6), 7.22–7.16 (m, 4H, Ar–H-3,4), 7.07 (d, 2H, $J=7.2$ Hz, Ar–H-5), 6.78 (d, 2H, $J=1.2$ Hz, Ar–H-2'), 6.72 (dd, 2H, $J=7.2, 1.2$ Hz, Ar–H-6'), 4.91 (s, 4H Ar–CH₂–O), 3.85 (s, 6H, OCH₃-3'), 3.80 (s, 6H, OCH₃-4'), 3.36 (ABq, 4H, $J=16.0$ Hz, Ar–CH₂–CO). ^{13}C NMR: δ 171.4 (C=O), 149.0 (Ar–C–OCH₃-4'), 148.9 (Ar–C–OCH₃-3'), 140.6 (Ar–C–H-3), 132.4 (Ar–C-1'), 130.2 (Ar–C–H-5), 130.1 (Ar–C–H-4), 128.5 (Ar–C-1), 127.7 (Ar–C–H-6), 126.9 (Ar–C-2'), 121.1 (Ar–C–H-6'), 111.6 (Ar–C–H-2'), 110.8 (Ar–C–H-5'), 66.9 (Ar–CH₂–O), 55.9 (Ar–OCH₃-4'), 55.8 (Ar–OCH₃-3'), 38.7 (Ar–CH₂–CO). MS: m/z (EI⁺) 570 (M⁺, 5%), 151 (100%). HRMS (EI⁺): calcd for C₃₄H₃₄O₈=570.2253 (M⁺), found 570.2239.

Acknowledgements

We thank Johnson and Johnson Research Pty. Limited, Sydney and the University of Wollongong for supporting this research and Dr. Wayne Gerlach for encouragement and support.

References and notes

- See for example: (a) Ames, D. E.; Opalko, A. *Tetrahedron* **1984**, *40*, 1919–1925; (b) Deshpande, P. P.; Martin, O. R. *Tetrahedron Lett.* **1990**, *31*, 6313–6316; (c) Hosoya, T.; Takashiro, E.;

- Matsumoto, T.; Suzuki, E. *J. Am. Chem. Soc.* **1994**, *116*, 1004–1015; (d) Qabaja, G.; Jones, G. B. *J. Org. Chem.* **2000**, *65*, 7187–7194; (e) Bringmann, G.; Menche, D. *Acc. Chem. Res.* **2001**, *34*, 615–624; (f) Bringmann, G.; Menche, D.; Muhlbacher, J.; Reichert, M.; Saito, N.; Pfeiffer, S. S.; Lipshutz, B. *Org. Lett.* **2002**, *4*, 2833–2836; (g) Molander, G. A.; George, K. M.; Monovich, L. G. *J. Org. Chem.* **2003**, *68*, 9533–9540; (h) Abe, H.; Takeda, S.; Fujita, T.; Nishioka, K.; Takeuchi, Y.; Harayama, T. *Tetrahedron Lett.* **2004**, *45*, 2327–2329; (i) Abe, H.; Nishioka, K.; Takeda, S.; Arai, M.; Takeuchi, Y.; Harayama, T. *Tetrahedron Lett.* **2005**, *46*, 3197–3200; (j) Cordero-Vargas, A.; Quiclet-Sire, B.; Zard, S. Z. *Org. Biomol. Chem.* **2005**, *3*, 4432–4443.
- For the synthesis of the corresponding lactams, see: (a) Harayama, T.; Kawata, Y.; Nagura, C.; Sata, T.; Miyagoe, T.; Abe, H.; Takeuchi, Y. *Tetrahedron Lett.* **2005**, *46*, 6091–6094; (b) Harayama, T.; Hori, A.; Abe, H.; Takeuchi, Y. *Heterocycles* **2006**, *67*, 385–390; (c) Campeau, L.-C.; Parisien, M.; Jean, A.; Fagnou, K. *J. Am. Chem. Soc.* **2006**, *128*, 581–590.
- Campeau, L.-C.; Fagnou, K. *Chem. Commun.* **2006**, 1253–1264.
- (a) Dyker, G. *Angew. Chem., Int. Ed.* **1999**, *38*, 1699–1712; (b) Larock, R. C.; Doty, M. J.; Cacchi, S. *J. Org. Chem.* **1993**, *58*, 4579–4583; (c) Campo, M. A.; Huang, Q.; Yao, T.; Tian, Q.; Larock, R. C. *J. Am. Chem. Soc.* **2003**, *125*, 11506–11507; (d) Huang, Q.; Fazio, A.; Dai, G.; Campo, M. A.; Larock, R. C. *J. Am. Chem. Soc.* **2004**, *126*, 7460–7461; (e) Huang, Q.; Campo, M. A.; Yao, T.; Tian, Q.; Larock, R. C. *J. Org. Chem.* **2004**, *69*, 8251–8257; (f) Torres, J. C.; Pinto, A. C.; Garden, S. J. *Tetrahedron* **2004**, *60*, 9889–9900; (g) Ma, S.; Gu, Z. *Angew. Chem., Int. Ed.* **2005**, *44*, 7512–7517; (h) Zhao, J.; Campo, M.; Larock, R. C. *Angew. Chem., Int. Ed.* **2005**, *44*, 1873–1875; (i) Barder, T. E.; Walker, S. D.; Martinelli, J. R.; Buchwald, S. L. *J. Am. Chem. Soc.* **2005**, *127*, 4685–4696; (j) Zhao, J.; Larock, R. C. *Org. Lett.* **2005**, *7*, 701–704; (k) Zhao, J.; Larock, R. C. *J. Org. Chem.* **2006**, *71*, 5340–5348; (l) Zhou, C.; Larock, R. C. *J. Org. Chem.* **2006**, *71*, 3551–3558; (m) Chen, X.; Goodhue, C. E.; Yu, J.-Q. *J. Am. Chem. Soc.* **2006**, *128*, 12634–12635; (n) Mota, A. J.; Dedieu, A. *Organometallics* **2006**, *25*, 3130–3142; (o) Zhao, J.; Yue, D.; Campo, M. A.; Larock, R. C. *J. Am. Chem. Soc.* **2007**, *129*, 5288–5295; (p) Campo, M. A.; Zhang, H.; Yao, T.; Ibdy, A.; McCulla, R. D.; Huang, Q.; Zhao, J.; Jenks, W. S.; Larock, R. C. *J. Am. Chem. Soc.* **2007**, *129*, 6298–6307.
- Churrua, F.; SanMartin, R.; Tellitu, I.; Dominguez, E. *Eur. J. Org. Chem.* **2005**, 2481–2490; Willis, M. C.; Taylor, D.; Gillmore, A. T. *Org. Lett.* **2004**, *6*, 4755–4757; Terao, Y.; Satoh, T.; Miura, M.; Nomura, M. *Bull. Chem. Soc. Jpn.* **1999**, *72*, 2345–2350.
- We thank a referee for drawing this possibility to our attention.
- (a) Fox, J. M.; Huang, X.; Chieffi, A.; Buchwald, S. L. *J. Am. Chem. Soc.* **2000**, *122*, 1360–1370; (b) Culkin, D. A.; Hartwig, J. F. *Acc. Chem. Res.* **2003**, *36*, 234–245.
- Beugelmans, R.; Bois-Choussy, M.; Chastanet, J.; Le Gleuher, M.; Zhu, J. *Heterocycles* **1993**, *36*, 2723–2732.
- Cheetham, P.; Samuel, J.; Bannister, N. E. PCT Int. Appl. WO 95 GB132519950607, 1995.